Evidence map›Paper›PMID 19521779›Full record

Trial reportPituitary2009

Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.

Agatha A van der Klaauw, Jeroen J Bax, Ferdinand Roelfsema, Marcel P M Stokkel, Gabe B Bleeker, Nienke R Biermasz, Johannes W A Smit, Johannes A Romijn, Alberto M Pereira

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pituitary, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    Trial
  4. Metabolic and quality of life effects of growth hormone replacement in patients with TBI and AGHD: A pilot study.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2023
    Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2016
    Observational
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Agatha A van der KlaauwDepartment of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. a.a.van_der_klaauw@lumc.nl
Jeroen J Bax
Ferdinand Roelfsema
Marcel P M Stokkel
Gabe B Bleeker
Nienke R Biermasz
Johannes W A Smit
Johannes A Romijn
Alberto M Pereira
Leiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to assess the effects of replacement with recombinant human growth hormone (rhGH) in patients with GH deficiency (GHD) after treatment of acromegaly. Intervention study. Sixteen patients (8 men, age 56 years), treated for acromegaly by surgery and radiotherapy, with an insufficient GH response to insulin-induced hypoglycaemia, were treated with 1 year of rhGH replacement. Study parameters were assessed at baseline and after 1 year of rhGH replacement. Study parameters were cardiac function, body composition, bone mineral density (BMD), fasting lipids, glucose, bone turnover markers, and Quality of Life (QoL). During rhGH replacement IGF-I concentrations increased from -0.4 +/- 0.7 to 1.0 +/- 1.5 SD (P = 0.001), with a mean daily dose of 0.2 +/- 0.1 mg in men and 0.3 +/- 0.2 mg in women. Nonetheless, rhGH replacement did not alter cardiac function, lipid and glucose concentrations, body composition or QoL. Bone turnover markers (PINP and beta crosslaps) levels increased (P = 0.005 and P = 0.021, respectively), paralleled by a small, but significant decrease in BMD of the hip. The beneficial effects of rhGH replacement in patients with GHD during cure from acromegaly are limited in this study.

Indexed as

Hormone Replacement TherapyAcromegalyAdultAgedBody CompositionBone DensityFemaleGlucoseHeartHuman Growth HormoneHumansHypopituitarismInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor ILipid MetabolismMaleGlucoseHuman Growth HormoneInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor I

Identifiers

PMID19521779
PMCPMC2764055
OpenAlexW2083097965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.